A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants of study V48P7 and long-term evaluation of immunogenicity up to 5 years after first booster immunization Descriptive evaluation of subjects with respect to antibody titers and percentage of subjects with neutralizing antibodies on Day 0 (i.e., day of first booster immunization after primary immunization ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2009/2010 when administered to adult and elderly subjects Immunogenicity Objectives To evaluate the antibody response to each influenza vaccine antigen, as measured by hemagglutination inhibition (HI) test on Day 0 and on Day 21, i.e., 21 days after vaccinat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2007/2008 when administered to adult and elderly subjects Immunogenicity Objectives To evaluate the antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21, i.e., 21 days after vaccina...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Subjects aged 6 months to 17 years To evaluate the safety and tolerability of and the magnitude of antibody responses to two 0.5mL intramuscular (IM) injections of FLUAD-H5N1 influenza vaccine each containing 7.5µg of A/H5N1 influenza ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects To assess the safety profile of FLUAD-H5N1 and to rule out an occurrence of an AE with a rate of 0.1% in Adults and 1% in Elderly subjects

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Primary To evaluate the magnitude of antibody responses to two doses of FLUAD-H5N1 influenza vaccine, each containing 7.5µg of H5N1 antigen administered 3 weeks apart.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of a single intramuscular dose of a trivalent subunit influenza vaccine produced in mammalian cell culture (Optaflu), using the strain composition 2007/2008, when administered to adult and elderly subjects Immunogenicity Objectives To evaluate the antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21, i.e., 21 days after immuniz...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2008/2009 when administered to adult and elderly subjects Immunogenicity Objectives To evaluate the antibody response to each influenza vaccine antigen, as measured by hemagglutination inhibition (HI) test on Day 0 and on Day 21, i.e., 21 days after vaccinat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (containing both interpandemic strains and H5N1) in adults aged 18 years and above Immunogenicity Objectives: To evaluate the magnitude of antibody responses to one 0.5 mL intramuscular (IM) dose of Aflunov given before or after one 0.5 mL intramuscular (IM) dose of a tetravalent ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase II, Multicenter, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adults Unprimed and Primed with MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines Evaluate the reactogenicity of H5N1 vaccination in a primed population (H5N3 adjuvanted or non-adjuvanted vaccine) compared to immunologically naïve subjects

• Pays Aucun
• Organes Aucun
• Spécialités Aucune